MSSA and MRSA are Staphylococcus aureus (S. aureus) bacteria with different resistance patterns. MRSA is resistant to many antibiotics and is more difficult to treat. Both types of bacteria can cause ...

Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track ...

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...

Please provide your email address to receive an email when new articles are posted on . Patients with low-risk methicillin-susceptible Staphylococcus aureus bacteremia who received short or prolonged ...

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that data ...

A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...

If the skin of a person’s nose becomes damaged, Staphylococcus aureus bacteria can enter the wound and cause an infection. Many people carry Staphylococcus aureus (S.aureus) on their skin or within ...

HONG KONG, Feb 11, 2020 - (ACN Newswire) - - Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet ...